Business
HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
HLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 29, 2019\n\n\n\nTORONTO, Jan. 29, 2019 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it has received the conditional approval of the Toronto Stock Exchange (\"TSX\") to graduate from the TSX Venture Exchange to list the Company's common shares on the TSX. \n\"Graduating to the TSX represents an important milestone for the Company as we continue to execute on our plan to build, and grow, a leading Canadian-based North American-focused specialty pharmaceutical company,\" said Greg Gubitz, CEO of HLS. \"Our listing on the TSX is expected to open our story to a broader network of investors, both here in Canada and abroad, therefore improving access to capital and enhancing liquidity.\"\nFinal approval of the listing is subject to HLS fulfilling certain standard and customary conditions required by the TSX on or before April 16, 2019. HLS expects that it will satisfy all requirements in due course and will issue further communication upon final approval from the TSX. Upon completion of these final listing requirements, HLS's common shares will begin trading on the TSX under the ticker \"HLS\" and will be subsequently delisted from the TSX Venture Exchange.\nABOUT HLS THERAPEUTICS INC.\nFormed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. \nFORWARD LOOKING INFORMATION\nThis releas...